Weight Loss, Category Gains - Corbion 2024 - 1

Weight Loss,
Category Gains
What Meat and Poultry Processors Need to Know About
Weight Loss Medications and New Market Opportunities
I
t's not an understatement to note that
glucagon-like peptide-1 receptor agonist
(GLP-1) medications have dramatically changed
the way many people eat and, moreover, the way
they think about food. The growing popularity of
these pharmaceutical interventions over the past
few years has transformed diets and mindsets
as well as the research and development of
new products, including protein offerings.
GLP-1 drugs are considered game changers
in the food and beverage industry. This class
of injectable and oral medications, including
those available under the brand names
Wegovy, Ozempic, Mounjaro and Zepbound,
were approved by the U.S. Food and Drug
Administration (FDA) to help treat Type 2
diabetes and obesity by mirroring a hormone
that the body uses to raise blood sugars to
necessary levels. These agonist drugs cause
slower digestion and affect parts of the brain
that process feelings of hunger and satiety.
Corbion has recognized the increasing use
of GLP-1 drugs and their impact on consumer
habits and taste preferences. Understanding
the critical role of food manufacturers in
adapting to these changes while maintaining
the quality of nutritious and delicious foods,
Corbion conducted proprietary research of
GLP-1 users to better understand their evolving
needs. This research was aimed to gather more
SDI Productions/Istock

Weight Loss, Category Gains - Corbion 2024

Table of Contents for the Digital Edition of Weight Loss, Category Gains - Corbion 2024

Weight Loss, Category Gains - Corbion 2024 - 1
Weight Loss, Category Gains - Corbion 2024 - 2
Weight Loss, Category Gains - Corbion 2024 - 3
Weight Loss, Category Gains - Corbion 2024 - 4
Weight Loss, Category Gains - Corbion 2024 - 5
Weight Loss, Category Gains - Corbion 2024 - 6
https://www.nxtbookmedia.com